Drugs / LYC-30937-EC
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02872285 | Dec 2016 → Jun 2017 | psoriasis | Lycera Corp. | Completed | Missed primary |
| Phase 2 | NCT02764229 | Nov 2016 → Jul 2018 | ulcerative colitis | Lycera Corp. | Terminated | No outcome recorded |
| Phase 2 | NCT02762500 | Jul 2016 → May 2018 | ulcerative colitis | Lycera Corp. | Completed | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LYC-30937-EC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02764229 ↗ |
| Route | Oral | “LYC-30937-EC given orally once daily” NCT02762500 ↗ |